Literature DB >> 22242910

Loss of multidrug and toxin extrusion 1 (MATE1) is associated with metformin-induced lactic acidosis.

K Toyama1, A Yonezawa, S Masuda, R Osawa, M Hosokawa, S Fujimoto, N Inagaki, K Inui, T Katsura.   

Abstract

BACKGROUNDS AND
PURPOSE: Lactic acidosis is a fatal adverse effect of metformin, but the risk factor remains unclear. Multidrug and toxin extrusion 1 (MATE1) is expressed in the luminal membrane of the kidney and liver. MATE1 was revealed to be responsible for the tubular and biliary secretion of metformin. Therefore, some MATE polymorphisms, that cause it to function abnormally, are hypothesized to induce lactic acidosis. The purpose of this study is to clarify the association between MATE dysfunction and metformin-induced lactic acidosis. EXPERIMENTAL APPROACH: Blood lactate, pH and bicarbonate ion (HCO(3) (-) ) levels were evaluated during continuous administration of 3 mg·mL(-1) metformin in drinking water using Mate1 knockout (-/-), heterozygous (+/-) and wild-type (+/+) mice. To determine the tissue accumulation of metformin, mice were given 400 mg·kg(-1) metformin orally. Furthermore, blood lactate data were obtained from diabetic patients given metformin. KEY
RESULTS: Seven days after metformin administration in drinking water, significantly higher blood lactate, lower pH and HCO(3) (-) levels were observed in Mate1(-/-) mice, but not in Mate1(+/-) mice. The blood lactate levels were not affected in patients with the heterozygous MATE variant (MATE1-L125F, MATE1-G64D, MATE2-K-G211V). Sixty minutes after metformin administration (400 mg·kg(-1) , p.o.) the hepatic concentration of metformin was markedly higher in Mate1(-/-) mice than in Mate1(+/+) mice. CONCLUSION AND IMPLICATIONS: MATE1 dysfunction caused a marked elevation in the metformin concentration in the liver and led to lactic acidosis, suggesting that the homozygous MATE1 variant could be one of the risk factors for metformin-induced lactic acidosis.
© 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22242910      PMCID: PMC3417438          DOI: 10.1111/j.1476-5381.2012.01853.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  28 in total

1.  Identification of multidrug and toxin extrusion (MATE1 and MATE2-K) variants with complete loss of transport activity.

Authors:  Moto Kajiwara; Tomohiro Terada; Ken Ogasawara; Junko Iwano; Toshiya Katsura; Atsushi Fukatsu; Toshio Doi; Ken-ichi Inui
Journal:  J Hum Genet       Date:  2009-01-09       Impact factor: 3.172

2.  Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2.

Authors:  Satohiro Masuda; Tomohiro Terada; Atsushi Yonezawa; Yuko Tanihara; Koshiro Kishimoto; Toshiya Katsura; Osamu Ogawa; Ken-ichi Inui
Journal:  J Am Soc Nephrol       Date:  2006-06-28       Impact factor: 10.121

Review 3.  Metformin.

Authors:  C J Bailey; R C Turner
Journal:  N Engl J Med       Date:  1996-02-29       Impact factor: 91.245

4.  SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid.

Authors:  Marja K Pasanen; Mikko Neuvonen; Pertti J Neuvonen; Mikko Niemi
Journal:  Pharmacogenet Genomics       Date:  2006-12       Impact factor: 2.089

5.  Role of AMP-activated protein kinase in mechanism of metformin action.

Authors:  G Zhou; R Myers; Y Li; Y Chen; X Shen; J Fenyk-Melody; M Wu; J Ventre; T Doebber; N Fujii; N Musi; M F Hirshman; L J Goodyear; D E Moller
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

6.  Lactic acidosis due to metformin therapy in a low risk patient.

Authors:  D J Tymms; B A Leatherdale
Journal:  Postgrad Med J       Date:  1988-03       Impact factor: 2.401

Review 7.  Metformin and lactic acidosis: cause or coincidence? A review of case reports.

Authors:  A M E Stades; J T Heikens; D W Erkelens; F Holleman; J B L Hoekstra
Journal:  J Intern Med       Date:  2004-02       Impact factor: 8.989

8.  SLCO1B1 variants and statin-induced myopathy--a genomewide study.

Authors:  E Link; S Parish; J Armitage; L Bowman; S Heath; F Matsuda; I Gut; M Lathrop; R Collins
Journal:  N Engl J Med       Date:  2008-07-23       Impact factor: 91.245

9.  Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters.

Authors:  Yuko Tanihara; Satohiro Masuda; Tomoko Sato; Toshiya Katsura; Osamu Ogawa; Ken-Ichi Inui
Journal:  Biochem Pharmacol       Date:  2007-04-13       Impact factor: 5.858

10.  Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study.

Authors:  Matthijs L Becker; Loes E Visser; Ron H N van Schaik; Albert Hofman; André G Uitterlinden; Bruno H Ch Stricker
Journal:  Diabetes       Date:  2009-02-19       Impact factor: 9.461

View more
  22 in total

Review 1.  Organic cation transporter OCTs (SLC22) and MATEs (SLC47) in the human kidney.

Authors:  Hideyuki Motohashi; Ken-ichi Inui
Journal:  AAPS J       Date:  2013-02-22       Impact factor: 4.009

2.  Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09).

Authors:  M Joerger; R H N van Schaik; M L Becker; S Hayoz; M Pollak; R Cathomas; R Winterhalder; S Gillessen; C Rothermundt
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-03-10       Impact factor: 5.554

Review 3.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

4.  The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin.

Authors:  Jennifer E Hibma; Arik A Zur; Richard A Castro; Matthias B Wittwer; Ron J Keizer; Sook Wah Yee; Srijib Goswami; Sophie L Stocker; Xuexiang Zhang; Yong Huang; Claire M Brett; Radojka M Savic; Kathleen M Giacomini
Journal:  Clin Pharmacokinet       Date:  2016-06       Impact factor: 6.447

Review 5.  Bile formation and secretion.

Authors:  James L Boyer
Journal:  Compr Physiol       Date:  2013-07       Impact factor: 9.090

6.  Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects.

Authors:  Dongseong Shin; Young Min Cho; SeungHwan Lee; Kyoung Soo Lim; Jeong-Ae Kim; Ji-Yung Ahn; Joo-Youn Cho; Howard Lee; In-Jin Jang; Kyung-Sang Yu
Journal:  Clin Drug Investig       Date:  2014-06       Impact factor: 2.859

7.  The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Volunteers.

Authors:  Kari M Morrissey; Sophie L Stocker; Eugene C Chen; Richard A Castro; Claire M Brett; Kathleen M Giacomini
Journal:  Clin Pharmacokinet       Date:  2016-04       Impact factor: 6.447

8.  Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters.

Authors:  Barbara Grün; Michael K Kiessling; Jürgen Burhenne; Klaus-Dieter Riedel; Johanna Weiss; Geraldine Rauch; Walter E Haefeli; David Czock
Journal:  Br J Clin Pharmacol       Date:  2013-11       Impact factor: 4.335

Review 9.  A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection.

Authors:  Stephen G Holt; David M Gracey; Miriam T Levy; David W Mudge; Ashley B Irish; Rowan G Walker; Richard Baer; Jacob Sevastos; Riaz Abbas; Mark A Boyd
Journal:  AIDS Res Ther       Date:  2014-11-10       Impact factor: 2.250

10.  Meta-Assessment of Metformin Absorption and Disposition Pharmacokinetics in Nine Species.

Authors:  Yoo-Seong Jeong; William J Jusko
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.